FilingSEC EDGAR8-K
Apimeds Pharmaceuticals Enters Agreement to Acquire Apitox Rights
· SEC accepted
StageAgreement Signed
Filing content
The company entered into an agreement to acquire rights from FreeT, including 100% of the Apitox market rights in Korea and a 25% royalty on U.S. commercialization proceeds.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…